EXEL

Exelixis, Inc., founded in 1994 and headquartered in Alameda, California, is a biopharmaceutical company focused on oncology. It develops and commercializes cancer treatments, with its flagship drug, cabozantinib, marketed as Cometriq for medullary thyroid cancer and Cabometyx for kidney, liver, and neuroendocrine tumors. The company also co-developed Cotellic with Roche for melanoma.

Exelixis uses genomics and model organisms to identify biological targets, advancing its pipeline with drugs like zanzalintinib. As of May 2025, its market cap is approximately $10.1 billion, with a stock price of $36.95 and trailing 12-month revenue of $2.3 billion. Despite setbacks, such as a failed trial in 2014, Exelixis continues to innovate in cancer treatment.